



Antengene to Attend Evercore China Biotech Summit and Participate in a Fireside Chat

Shanghai and Hong Kong, PRC, August 15, 2025 — Antengene Corporation Limited (**“Antengene”** , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that **it will attend the Evercore China Biotech Summit, to be held from August 19th to 21st at the Ritz-Carlton Shanghai, Pudong. During the event, Antengene will provide an update on its R&D progress as well as its strategic initiatives in a featured fireside chat.**

The summit, organized and hosted by Evercore ISI, a world-leading independent investment banking advisory firm, will bring together biotech industry leaders, top analysts, as well as investors from Europe and the U.S. to discuss the latest trends and investment opportunities in the biopharmaceutical sector. The event serves as an important platform connecting China’s innovative drug companies with global investors.

Fireside Chat:

Dr. Jay Mei, Antengene’s Founder, Chairman, and CEO

Time: August 21, 2025, Thursday, 11:45 – 12:05 Beijing Time

Venue: Grand Ballroom 2 & 3, The Ritz-Carlton Shanghai, Pudong

The following members of the management team will also attend the conference:

Mr. Donald Lung Chief Financial Officer

Mr. Kevin Cao Corporate Vice President and Board Secretary

Ms. Ariel Guo Vice President, Business Development / Chief of Staff



We look forward to connecting with attendees to exchange insights on biotech industry trends, explore new opportunities for growth and collaboration, and work together to accelerate the industry's dynamic growth and innovation.

About Antengene

Antengene Corporation Limited (**“Antengene”** , SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia.

Forward-looking statements



The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.